Directors

Dr Rod Adams - Chairman

Rod was a founder and Managing Director of Adams Healthcare Limited, a business focused on prescription and hospital dermatology products and infection control. Rod led the management buyout of Adams Healthcare Limited from DePuy International Limited in 1997. Adams Healthcare Limited was acquired by Medical Solutions plc in 2000 with Rod becoming Chief Operating Officer of that company and also maintaining his position as Managing Director of Adams Healthcare Limited. In 2002, he sold the Adams Healthcare division of Medical Solutions to Ecolab Inc., becoming European Projects Director for Ecolab, based in Germany, until 2004. Rod became a shareholder of Syntopix and was then appointed to the Syntopix Board in October 2004.

Dr Stephen P. Jones - Chief Executive Officer

Stephen is a highly experienced pharmaceutical industry executive with a track record in both branded medicines and consumer healthcare and a successful history of new product development. At Syntopix, he co-ordinates operational activities and commercial relationships. Stephen was most recently at GlaxoSmithKline (GSK) where he held the position of Vice President and Director of Consumer Healthcare Research and Development. Prior to joining GSK Stephen worked for companies including Scherer Drug Delivery Systems, Sterling Winthrop, Beecham Pharmaceutical's Research Division, Merck Sharp & Dohme and Amersham International.

Dr Anne Eady - Scientific Director

Anne is a founder shareholder of Syntopix and is an internationally recognised skin microbiologist, with particular expertise in acne, acne clinical trial methodology and the dermatological use of antibiotics. She has worked extensively with clinicians and pharmaceutical companies on a variety of basic and applied research projects and has advised on microbiological aspects of a number of regulatory submissions. Anne is an Honorary Research Fellow in Dermatology at Harrogate District Hospital.

Dr Jon Cove - Research Director

Jon is a founder shareholder of Syntopix and is currently seconded to the Group from the University of Leeds, where he is a senior lecturer at the Institute of Molecular and Cellular Biology. Jon's areas of expertise are in the evolution and mechanisms of antibiotic resistance in skin bacteria and he has previous experience of working in the pharmaceutical industry. In collaboration with Anne Eady, Jon has established research and/or consultancy with commercial sponsors, including Galderma, Roche, Sanofi-Aventis, Unilever, Stiefel, Smith and Nephew and ProStrakan.

Darren Bamforth - Finance Director

Darren is a Chartered Accountant and a Director of Atraxa Consulting Limited, his own business advisory practice which specialises in supporting early stage and growing companies. Darren has been the Finance Director of the Group, on a consultancy basis, since the formation of Syntopix. Prior to establishing his own practice in 2002, Darren was a Senior Manager with KPMG.

Dr Gwyn Humphreys - Senior Non-executive Director

Gwyn was a founder and Managing Director of Bradford Particle Design Limited, a successful UK university spin-out company, which developed supercritical fluid technology used to control particle size in drug formulation. Bradford Particle Design Limited was sold in January 2001 to Inhale Therapeutics Inc. (since re-named Nektar Therapeutics Inc.) for $200 million. Gwyn became a shareholder of Syntopix and was then appointed Chairman of Syntopix in October 2004. Gwyn is a member of the Nomination Committee, Remuneration Committee and Audit Committee.

Alan Aubrey - Non-executive Director

Alan established Techtran Group Limited, the intellectual property commercialisation partner of the University of Leeds, in 2002 and was its Chief Executive Officer when the business was acquired by IP2IPO Group plc in January 2005. Previously he was a partner in KPMG where he specialised in corporate finance advice to technology-based, fast-growth businesses and has significant experience in helping them raise money and prepare for sale or flotation. Alan is a qualified Chartered Accountant and is now the Chief Executive Officer of IP2IPO Group plc, a substantial shareholder in the Company through its subsidiary Techtran Group Limited. Alan is a member of the Nomination Committee, Remuneration Committee and Audit Committee.

Dr Helen Shaw - Non-executive Director

Helen qualified with a degree in medicine and worked as a medical practitioner for a number of years before entering the pharmaceutical industry. She worked for Boots Healthcare International from 1995 until January 2006, becoming Medical Director in May 2003. Helen was responsible for clinical and medical aspects of global product development including idea generation, regulatory submission and in-market support. Helen's portfolio included Clearasil and E45. Reckitt Benckiser acquired Boots Healthcare International for £1.9 billion in February 2006. Helen joined the Board of Syntopix in January 2006. Helen is Chairman of the Nomination Committee, Remuneration Committee and Audit Committee.

Employees

The Group also employs nine scientists and support staff who work at the Group's registered office.

COPYRIGHT 2008 SYNTOPIX GROUP PLC, SYNTOPIX IS A REGISTERED TRADEMARK ACCESSIBILITY STATEMENT SITE MAP TEXT ONLY VERSION TERMS & CONDITIONS